Compare Adecoagro SA (AGRO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Neurocrine Biosciences Inc — how do they compare? Adecoagro SA trades at $9.67 (market cap $1.39B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 12.1× Adecoagro SA's market cap, and Adecoagro SA pays a 3.07% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AGRO | NBIX | |
|---|---|---|
Market Cap | $1.39B | $16.76B |
Sector | Technology | Health |
52-Week High | $15.25 | $185.50 |
52-Week Low | $7.13 | $123.10 |
Enterprise Value | $3.43B | $16.78B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.45, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported negative net income of -$8.35M for 2025 despite $1.43B revenue, though 2026 projections show potential profitability improvement. Recent acquisition of Caarapó Mill expands operational footprint while analyst consensus leans neutral with 50% hold ratings.
Outlook remains cautious with elevated P/E ratio of 536.67 offset by attractive P/B of 0.79. Key risks include commodity volatility and integration challenges from recent acquisitions. The stock presents value opportunity if 2026 profitability targets are achieved, but requires careful monitoring of earnings trajectory.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
